dc.contributorGarc�a-Ba�uelos, J., Departamento de Biolog�a Molecular y Gen�mica, Instituto de Biolog�a Molecular en Medicina y Terapia G�nica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Panduro, A., Servicio de Biolog�a Molecular, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico; Gordillo-Bastidas, D., Departamento de Biolog�a Molecular y Gen�mica, Instituto de Enfermedades Cr�nico-Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Gordillo-Bastidas, E., Departamento de Biolog�a Molecular y Gen�mica, Instituto de Enfermedades Cr�nico-Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Mu�oz-Valle, J.F., Departamento de Biolog�a Molecular y Gen�mica, Instituto de Investigaci�n en Reumatolog�a y del Sistema M�sculo Esqueletico, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Gurrola-D�az, C.M., Departamento de Biolog�a Molecular y Gen�mica, Instituto de Enfermedades Cr�nico-Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; S�nchez-Enr�quez, S., Laboratorio de Bioqu�mica, Departamento de Biolog�a Molecular y Gen�mica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Ruiz-Madrigal, B., Servicio de Biolog�a Molecular, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico; Bastidas-Ram�rez, B.E., Departamento de Biolog�a Molecular y Gen�mica, Instituto de Enfermedades Cr�nico-Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
dc.contributorPanduro-Cerda, Arturo., Universidad de Guadalajara
dc.creatorGarcia-Banuelos, J.
dc.creatorPanduro-Cerda, Arturo
dc.creatorGordillo-Bastidas, D.
dc.creatorGordillo-Bastidas, E.
dc.creatorMunoz-Valle, J.F.
dc.creatorGurrola-Diaz, C.M.
dc.creatorSanchez-Enriquez, S.
dc.creatorRuiz-Madrigal, B.
dc.creatorBastidas-Ramirez, B.E.
dc.date.accessioned2015-09-15T18:02:15Z
dc.date.accessioned2022-11-02T15:16:46Z
dc.date.available2015-09-15T18:02:15Z
dc.date.available2022-11-02T15:16:46Z
dc.date.created2015-09-15T18:02:15Z
dc.date.issued2012
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84857505901&partnerID=40&md5=0d6500b2def4fea589042bab8af49dc3
dc.identifierhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21895718
dc.identifierhttp://hdl.handle.net/20.500.12104/41703
dc.identifier10.1111/j.1530-0277.2011.01617.x
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5011686
dc.description.abstractBackground: Alcoholic cirrhosis constitutes a major public health problem in the world where ADH1B, ALDH2, and CYP2E1 polymorphisms could be playing an important role. We determined ADH1B*2, ALDH2*2, and CYP2E1*c2 allele frequencies in healthy control individuals (C) and patients with alcoholic cirrhosis (AC) from western Mexico. Methods: Ninety C and 41 patients with AC were studied. Genotype and allele frequency were determined through polymerase chain reaction-restriction fragment length polymorphisms. Results: Polymorphic allele distribution in AC was 1.6%ADH1B*2, 0.0%ALDH2*2, and 19.5%CYP2E1*c2; in C: 6.1%ADH1B*2, 0%ALDH2*2, and 10.6%CYP2E1*c2. CYP2E1*c2 polymorphic allele and c1/c2 genotype frequency were significantly higher (p<0.05 and p<0.01, respectively) in patients with AC when compared to C. Patients with AC, carrying the CYP2E1*c2 allele, exhibited more decompensated liver functioning evaluated by total bilirubin and prothrombin time, than c1 allele carrying patients (p<0.05). Cirrhosis severity, assessed by Child's Pugh score and mortality, was higher in patients carrying the c2 allele, although not statistically significant. Conclusions: In this study, CYP2E1*c2 allele was associated with susceptibility to AC; meanwhile, ADH1B*2 and ALDH2*2 alleles were not. CYP2E1*c2 allele was associated with AC severity, which could probably be attributed to the oxidative stress promoted by this polymorphic form. Further studies to clearly establish CYP2E1*c2 clinical relevance in the development of alcohol-induced liver damage and its usefulness as a probable prognostic marker, should be performed. Also, increasing the number of patients and including a control group conformed by alcoholic patients free of liver damage may render more conclusive results. These findings contribute to the understanding of the influence of gene variations in AC development among populations, alcohol metabolism, and pharmacogenetics. � 2011 by the Research Society on Alcoholism.
dc.relationScopus
dc.relationMEDLINE
dc.relationWOS
dc.relationAlcoholism: Clinical and Experimental Research
dc.relation36
dc.relation3
dc.relation425
dc.relation431
dc.titleGenetic Polymorphisms of Genes Coding to Alcohol-Metabolizing Enzymes in Western Mexicans: Association of CYP2E1*c2/CYP2E1*5B Allele with Cirrhosis and Liver Function
dc.typeArticle


Este ítem pertenece a la siguiente institución